Delali Blavo, DO
Endocrinology, Diabetes & Metabolism · Southaven, MSNPI 1538430244
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,609 of the $148,234 with a category attached, or 71.9%. Corcept Therapeutics accounts for 83.0% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $59,040, more than ten times the $1,493 reported in 2019.
Across 864 payments — averaging $171.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$123K
- Xeris Pharmaceuticals, Inc.$7K
- Cequr Corporation$4K
- Lilly USA, LLC$2K
- Medtronic$2K
- Novo Nordisk$2K
- plus $8K from 35 others
What the payments were for
- Consulting fees$6000%
- Speaking & faculty fees$106,60972%
- Travel & lodging$20,26514%
- Food & beverage$20,70614%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$119,733
- RECORLEV$6,062
- CeQur Simplicity$4,259
- MINIMED 780G$442
- MOUNJARO$320
- FARXIGA$312
- Omnipod$239
- FreeStyle Libre$227
- ISTURISA$226
- AFREZZA$135
- FREESTYLE LIBRE 3$132
- MYALEPT$125
- TEPEZZA$124
- Ozempic$122
- Minimed 630G$111
- DEXCOM G7 GSS (161)$111
How this compares
$148,234 in reported general payments places this provider in the 85th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 108 | $3,596,141 |
| OzempicSemaglutide | 214 | $275,859 |
| MounjaroTirzepatide | 105 | $125,736 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $123,244 |
| FarxigaDapagliflozin Propanediol | 95 | $97,411 |
| TrulicityDulaglutide | 45 | $70,065 |
| JardianceEmpagliflozin | 57 | $68,952 |
| JanuviaSitagliptin Phosphate | 61 | $60,981 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $55,464 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $41,512 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $40,735 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $27,621 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $27,153 |
| KerendiaFinerenone | 21 | $20,959 |
| Gvoke Hypopen 2-PackGlucagon | 34 | $20,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $123,066 | $3,596,141108 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,515 | $320,281274 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,347 | $195,800150 claims |
| AstraZenecaFarxiga | $812 | $97,41195 claims |
| Boehringer IngelheimJardiance, Tradjenta | $834 | $88,18576 claims |
| MerckJanuvia, Janumet | $184 | $66,90972 claims |
| BayerKerendia | $462 | $20,95921 claims |
| Cequr CorporationCequr Simplicity | $4,270 | $11,24619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Southaven
- Francesca WilkinsSouthaven$4K
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- John SistrunkJackson$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.